The mainly partisan disagreements in Congress over whether the Medicare price negotiation program established by the Inflation Reduction Act will undercut pharmaceutical industry innovation took center stage at a House Energy & Commerce Health Subcommittee hearing on legislation to support rare disease patients on 29 February.
IRA Innovation Debate Showcased At House Hearing On Rare Disease Legislation
Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.
